Two-Pronged attack tested against tough head and neck cancers
NCT ID NCT03993353
Summary
This study tested whether combining two existing drugs—pembrolizumab (an immunotherapy) and tadalafil—could be safe and more effective for people with advanced head and neck cancer that has returned or spread. The idea was to boost the body's immune system in two different ways to fight the cancer. It was a small, early-phase trial involving 7 participants to check safety and see if the approach showed promise.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
Conditions
Explore the condition pages connected to this study.